We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
Read MoreHide Full Article
Celyad Oncology SA (CYAD - Free Report) entered into a clinical trial collaboration with Merck (MRK - Free Report) to evaluate its investigational non-gene edited allogeneic CAR T candidate, CYAD-101, combined with the latter’sblockbuster anti-PD-1 drug, Keytruda, in patients with microsatellite stable refractory metastatic colorectal cancer (mCRC).
Celyad Oncology will conduct the phase Ib KEYNOTE-B79 study. The study will evaluate CYAD-101 in combination with Keytruda, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapyin refractory mCRC patients with microsatellite stable disease. FOLFIRI is a chemotherapy regimen for the treatment of colorectal cancer.
Shares of Ceylad have lost 10.8% against the industry’s 2.2% growth.
According to Celyad, the mechanisms of both CYAD-101 and Keytruda are complementary and could help drive meaningful clinical benefits in patients with advanced mCRC.
Ceylad is evaluating CYAD-101 for the treatment of mCRC in a phase I alloSHRINK study.
The company released additional data from the study in June 2020. The study demonstrated CYAD-101’s differentiated profile as an allogeneic CAR-T candidate. Two patients achieved a confirmed partial response and nine patients achieved stable disease, leading to a disease control rate of 73%. Overall safety and clinical activity data are human leukocyte antigen (HLA)-independent, indicating that CYAD-101 cells can be used in a broad patient population regardless of the HLA haplotype.
Per Celyad, the Merck collaboration will help it further build on the encouraging data from the alloSHRINK study.
Emergent’s earnings estimates have increased from $4.23 to $6.58 for 2020 and from $5.55 to $7.62 for 2021 over the past 60 days. Shares of the company have increased 92.1% year to date.
Bio Techne’s earnings estimates have increased from $5.33 to $5.48 for 2020 and from $6.41 to $6.50 for 2021 over the past 60 days. Shares of the company have increased 11.0% year to date.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year. These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
Celyad Oncology SA (CYAD - Free Report) entered into a clinical trial collaboration with Merck (MRK - Free Report) to evaluate its investigational non-gene edited allogeneic CAR T candidate, CYAD-101, combined with the latter’sblockbuster anti-PD-1 drug, Keytruda, in patients with microsatellite stable refractory metastatic colorectal cancer (mCRC).
Celyad Oncology will conduct the phase Ib KEYNOTE-B79 study. The study will evaluate CYAD-101 in combination with Keytruda, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapyin refractory mCRC patients with microsatellite stable disease. FOLFIRI is a chemotherapy regimen for the treatment of colorectal cancer.
Shares of Ceylad have lost 10.8% against the industry’s 2.2% growth.
According to Celyad, the mechanisms of both CYAD-101 and Keytruda are complementary and could help drive meaningful clinical benefits in patients with advanced mCRC.
Ceylad is evaluating CYAD-101 for the treatment of mCRC in a phase I alloSHRINK study.
The company released additional data from the study in June 2020. The study demonstrated CYAD-101’s differentiated profile as an allogeneic CAR-T candidate. Two patients achieved a confirmed partial response and nine patients achieved stable disease, leading to a disease control rate of 73%. Overall safety and clinical activity data are human leukocyte antigen (HLA)-independent, indicating that CYAD-101 cells can be used in a broad patient population regardless of the HLA haplotype.
Per Celyad, the Merck collaboration will help it further build on the encouraging data from the alloSHRINK study.
Zacks Rank & Stocks to Consider
Celyad currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) and Bio Techne Corp (TECH - Free Report) . While Emergent Biosolutions sports a Zacks Rank #1 (Strong Buy), Bio Techne carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $4.23 to $6.58 for 2020 and from $5.55 to $7.62 for 2021 over the past 60 days. Shares of the company have increased 92.1% year to date.
Bio Techne’s earnings estimates have increased from $5.33 to $5.48 for 2020 and from $6.41 to $6.50 for 2021 over the past 60 days. Shares of the company have increased 11.0% year to date.
Celyad SA Price
Celyad SA price | Celyad SA Quote
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year. These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>